Selective H3 Receptor Modulators via Local Quality Substitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modulators of H3 receptors lack specificity and efficacy in treating central nervous system disorders, with existing compounds often exhibiting activity at unintended receptor sites, such as the MCH-1 receptor.
Innovation Solution
Development of substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides that act as selective H3 receptor antagonists or inverse agonists, specifically designed to target H3 receptors with minimal activity at the MCH-1 receptor site, allowing for targeted treatment of H3 receptor-mediated CNS disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing H3 receptor modulators are used, then therapeutic effects are achieved, but specificity is poor and off-target activity occurs at MCH-1 receptor site
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions on the phenyl ring (positions 2, 4, or 6) of the N-phenyl-pyrrolidinylmethylpyrrolidine amide core structure. These localized structural modifications enhance binding selectivity for H3 receptors while minimizing interaction with MCH-1 receptors, thereby improving specificity and reducing off-target activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical nature of substituents (R1, R2, R3, R4) at different positions of the molecular structure. By changing parameters such as substituent type, position, and configuration, the patent optimizes the balance between H3 receptor affinity and MCH-1 receptor selectivity, achieving improved therapeutic profiles.
2Reliability
If selective H3 receptor ligands are designed, then off-target effects are reduced, but structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules: a core N-phenyl-pyrrolidinylmethylpyrrolidine amide framework and variable substituent groups (R1, R2, R3, R4) at specific positions. This modular approach allows systematic optimization of selectivity while maintaining a manageable structural basis for synthesis and development.
Data Source
AI summary
The present invention discloses and claims a series of substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides of formula (I) as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted pyrrolidinylmethylpyrrolidine amides and intermediates therefor.